o-(chloroacetylcarbamoyl)fumagillol and Medulloblastoma

It has been shown that angiogenesis plays an important role in pathological conditions including the growth of solid tumors. Furthermore, it is thought that anti-angiogenic agents might be clinically useful for therapy of these diseases. TNP-470 (TNP), a synthetic analog of fumagillin isolated from Aspergillus fumigatus, was used as an anti-angiogenic agent in this study in a nude mouse model with a subcutaneously implanted fragment of medulloblastoma. After treatment with this agent for 4 weeks, the inhibition rates of tumor growth were as follows: 15.9% in the group given 1 mg/kg, 16.9% with 10 mg/kg, 29.6% with 30 mg/kg, 49.9% with 50 mg/kg and 65.7% with 100 mg/kg. TNP inhibited the growth of brain tumor dose-dependently and induced various ischemic changes within the tumor tissue. Therefore, TNP may be effective for the treatment of malignant brain tumors such as medulloblastoma.

Topics: Animals; Antibiotics, Antineoplastic; Cell Division; Cell Line; Cell Survival; Cerebellar Neoplasms; Child; Cyclohexanes; Dose-Response Relationship, Drug; Female; Humans; Medulloblastoma; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; O-(Chloroacetylcarbamoyl)fumagillol; Sesquiterpenes; Tumor Cells, Cultured